Endo Pharmaceuticals, BioDelivery Sciences Present Promising Data On New Chronic Pain Management Product

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc - Ordinary Shares ENDP and BioDelivery Sciences International, Inc. BDSI presented data from a Phase 2 study for HCl buccal film.

The stocks failed to surge on the news.

However, BioDelivery’s stock did rise due to other news.

In the context of the PAINWeek 2015, Endo Pharmaceuticals Inc. and BioDelivery Sciences International presented promising data from a “Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA®) drug delivery technology,” according to their Press Release.

The results showed that the participants receiving around-the-clock therapy with an opioid full agonist could switch to buprenorphine HCl buccal film (BELBUCA), receiving roughly half the full agonist dose, without seeing an increase in the risk of experiencing opioid withdrawal or a decrease in pain relief.

What The Findings Mean Going Forward

"Our findings could have important implications for future strategies to broaden the treatment options for patients living with pain who require around-the-clock opioid treatment,” Lynn Webster, M.D., vice president of scientific affairs at PRA Health Sciences, lead study investigator and former president of the American Academy of Pain Medicine explained.

Despite Wednesday's good news, Endo International plc’s stock fell 2.1 percent and BioDelivery Sciences International’s stock surged by a miniscule 0.15 percent.

On Thursday, however, both stocks were on the rise. Endo gained more than 0.5 percent, while BioDelivery Sciences returned 5.7 percent.

Good News For BioDelivery

It should be noted, however, that the latter is also surging on another announcement: The company has closed a two-year agreement with Tennessee Medicaid, also known as TennCare. According to the deal, Bunavail, BioDelivery’s opiod-dependence drug, will become “the only buprenorphine/naloxone treatment for opioid dependence to gain preferred coverage status on TennCare's preferred drug list (PDL).”

Image Credit: Public Domain

Market News and Data brought to you by Benzinga APIs